Abstract-The biological actions of bradykinin (BK) are attributed to its B 2 type receptor (B 2 R), whereas the B 1 R is constitutively absent, inducible by inflammation and toxins. Previous studies in B 2 R gene knockout mice showed that the B 1 R is overexpressed, is further upregulated by hypertensive maneuvers, and assumes some of the hemodynamic functions of the B 2 R. The current experiments were designed to further clarify the metabolic function of the B 2 R and to explore whether the upregulated B 1 R can also assume the metabolic function of the missing B 2 R. One group of B 2 RϪ/Ϫ mice (nϭ9) and one of B 2 Rϩ/ϩ controls (nϭ8) were treated for 3 days with captopril (which produced a similar blood pressure-lowering response in both groups) and studied with the hyperinsulinemic euglycemic clamp. The knockout mice had fasting and steady-state blood glucose levels similar to those of the wild-type mice but a had tendency to higher fasting insulin levels (at 27.8Ϯ5.2 versus 18Ϯ2.9 mU/L, respectively). However, they had significantly higher steady-state insulin levels (749Ϯ127. radykinin mediates a variety of biological effects such as vasodilation, vascular permeability, inflammation, pain, and edema. 1 It is also known to play an important role in glucose metabolism. 2,3 Indeed, it was shown in vitro and in vivo that administration of bradykinin increases the glucose uptake in cultured adipocytes 4 as well as in long-term rat experiments 5 and in skeletal muscle of human forearm. 6 ACE inhibitors were shown to improve glucose utilization, 7 an action that is attributed to bradykinin. 8, 9 In keeping with these data, kininogen-deficient rats were found to be resistant to insulin. 10 The effects of bradykinin are mediated by the B 1 -or B 2 -type receptor (B 1 R or B 2 R). It has been accepted that almost all of the physiologically significant effects of bradykinin, including the metabolic ones, are exerted by activation of the B 2 R. Indeed, inhibition of the B 2 R by various antagonists was shown to reverse the amelioration of insulindependent glucose transport by ACE inhibitors, 11,12 whereas blockade of downstream mediators, such as prostaglandins and NO, had no effect on insulin sensitivity. 12 Several studies have shown that the B 2 R is expressed in tissues dependent on insulin for glucose uptake, such as skeletal muscle and adipocytes. 4, 13, 14 On the contrary, the B 1 R is not expressed under normal conditions; it has long been known that its expression is induced by toxins or inflammatory mediators and it contributes to endotoxic shock, 15 but it has not been associated with metabolic functions.
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In a recent series of studies, investigators have used genetically engineered mice with deleted B 2 R 16 to further explore the physiological actions of bradykinin. Using these mice, we observed that the B 1 R is highly expressed in B 2 R knockout mice and appears to take over some of the hemodynamic properties of the B 2 R. 17 The present experiments were designed to further explore the metabolic function of the B 2 R and to investigate whether in the absence of B 2 R, the upgraded B 1 R might also be able to take over the metabolic functions of bradykinin. To this aim, we evaluated the differences in insulin sensitivity in B 2 R knockout mice and their wild-type controls, by using the hyperinsulinemic euglycemic clamp technique.
Methods

Animals
Bradykinin B 2 R gene knockout mice (B 2 RϪ/Ϫ) 16 and their wild-type B6 129SvF2 controls (B 2 Rϩ/ϩ), obtained from the Jackson Labo-ratories (Bar Harbor, Maine), were used in this study. All experiments were conducted in accordance with the guidelines for the Care and Use of Animals approved by the Boston University Medical Center.
Blood Pressure and Heart Rate Monitoring
Systolic blood pressure (SBP) and heart rate were determined with the use of a noninvasive computerized tail-cuff system (BP-2000 Visitech Systems), as described elsewhere. 18 After baseline measurements, 2 groups of mice, one B 2 RϪ/Ϫ (nϭ9) and one of their wild-type counterparts (nϭ8), were given 100 mg/kg per day captopril (Sigma Chemical Co) in their drinking water for a period of 3 days.
Euglycemic Hyperinsulinemic Clamp Procedure
Under anesthesia with pentobarbital (50 mg/kg IP), two catheters were inserted in the left jugular vein for infusion of glucose and insulin and one in the iliac artery for blood sampling. 12 The mice were maintained supine throughout the 2-hour duration of the procedure on a heating pad at 37°C. Anesthesia was confirmed by the absence of corneal and toe-pinch reflexes. Porcine insulin (Eli Lilly & Co) was infused at a rate 12 mUI/kg per minute, and 5% glucose was infused through a Harvard pump (Harvard Apparatus Inc) at variable rates as needed to maintain euglycemia. Blood samples (10 L) were collected every 5 to 10 minutes from the iliac artery and assayed by the Accu-ChecII blood glucose monitor; 250 L of blood was withdrawn to measure plasma insulin levels at time zero and at the end of the hyperinsulinemic infusion. A donor mouse was used to replace the blood withdrawn at the beginning of the experiment. Plasma insulin levels were measured by a rat immunoassay kit (Linco Research).
The following parameters were recorded: (1) fasting plasma glucose and insulin levels, (2) plasma glucose levels at each of the 6 to 8 samplings throughout the clamp period, (3) steady-state plasma glucose levels as reflected by the mean of the plasma glucose levels in the last 30 minutes of the clamp, (4) plasma insulin level at the end of the clamp, and (5) glucose uptake as reflected by the mean glucose amount delivered in the last 30 minutes of the clamp. The insulin sensitivity index was calculated as the ratio of glucose uptake (mg/kg per minute) to steady-state plasma insulin level (mU/L)ϫ10 2 .
Expression of Bradykinin Receptors in Tissues
Total RNA was prepared from heart, skeletal muscle, and adipose tissue, with TRIzol Reagent (GIBCO BRL). A DNase digestion step was performed to increase the purity of the RNA samples with total RNA Isolation Kit S.N.A.P. (Invitrogen). The expression of B 1 R and B 2 R in the heart, skeletal muscle, and adipose tissues was examined by reverse transcription-polymerase chain reaction (RT-PCR) techniques as previously described. 17
Statistical Analysis
All data are expressed as meanϮSEM. Student's t tests for paired and unpaired data were used as appropriate. The Mann-Whitney rank sum test was used for nonparametric data. Differences at PϽ0.05 were considered significant.
Results
SBP at baseline and after treatment with captopril are shown in Figure 1 . Fasting glucose and insulin were within normal ranges in both groups, (although insulin did tend to be higher in the knockouts), but the knockout mice had higher steady-state insulin levels and lower glucose uptake compared with the wild-type mice. As a result, the insulin sensitivity index was significantly decreased in the B 2 R gene knockouts.
The B 1 R and B 2 R mRNA expression in tissues was determined by means of a semiquantitative RT-PCR assay. The data of B 1 R mRNA in skeletal muscle at baseline (captopril-treated animals, with no further treatment) and at end point (after hyperinsulinemic euglycemic clamp) are presented in Figure 2A . Insulin infusion induced a 2.3-fold increase of B 1 R mRNA expression over baseline (PϽ0.05) in wild-type mice and a further 1.9-fold (PϽ0.05) increment in the knockout mice, in which the B 1 R was already overexpressed at baseline. The level of B 1 R mRNA expression was significantly higher (PϽ0.05) in the B 2 RϪ/Ϫ mice compared with the B 2 Rϩ/ϩ at both baseline and end point. The B 2 R mRNA levels in skeletal muscle are shown in Figure 2B . Insulin infusion induced a 1.8-fold increase over baseline (PϽ0.05) in B 2 R expression in wild-type mice. As expected, there was no B 2 R mRNA in the knockout mice. Figure 3 shows the B 1 R mRNA expression (panel A) and B 2 R expression (panel B) in adipose tissue at baseline and end point. The B 1 R expression was upregulated 1.6-fold over baseline (PϽ0.05) in both knockout and wild-type mice. Figure 3B shows a 3.2-fold increase in B 2 R expression over baseline (PϽ0.05) in the wild-type mice submitted to hyperinsulinemic euglycemic clamp.
The data of BR mRNA expression in heart are presented in Figure 4 . Panel A shows that B 1 R is already overexpressed in the knockouts at baseline and is further upregulated in both knockout and wild-type mice after insulin infusion by 1.6-and 1.9-fold over baseline, respectively (PϽ0.05). Figure 4B shows that the procedure induced a 2.8-fold (PϽ0.05) increase in B 2 R expression over the control level in wild-type mice.
Discussion
This study used the hyperinsulinemic euglycemic clamp technique to evaluate the impact of the absence of the B 2 R on insulin-dependent glucose transport. Although studies without ACE inhibition would better reflect physiological conditions, we chose to use pretreatment with ACE inhibition to maximize the influence of endogenous bradykinin. We found that animals lacking the B 2 R had a similar BP response to the ACE inhibitor as the wild-type animals but exhibited relative insulin resistance, as shown by tendency to elevated fasting insulin levels that were further exaggerated during hyperinsulinemic conditions under ACE inhibition. Although elevated insulin levels could be attributable to reduced insulin clearance, their presence in the face of normoglycemia is 
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characteristic of diminished tissue sensitivity to insulin. Glucose uptake was reduced by 25% and the insulin sensitivity index by 54% compared with the wild-type mice. The data indicate that absence of B 2 R causes a state of insulin resistance, as it is associated with impaired glucose metabolism. This is in agreement with previous data, which have shown that selective antagonists of the B 2 R decrease glucose uptake and insulin sensitivity and abolish the improvement in insulin sensitivity produced by ACE inhibitors. 9, 11, 12 The contribution of bradykinin to glucose metabolism was suggested years ago, when in vitro and in vivo studies demonstrated that exogenous administration of bradykinin improved insulin sensitivity. 19, 20 It has been shown that bradykinin enhances insulin receptor phosphorylation and insulin-stimulated translocation of GLUT4 from cytosol to plasma membrane. 4, 21 A recent study in 32D cells demonstrated that bradykinin enhances the activity of the insulin receptor and downstream insulin signaling cascade through the B 2 R-mediated signal pathway. 22 Inhibition of the ACE, which is identical to the kininase II that mediates degradation of kinins, 23 results in potentiation of bradykinin effects. It is therefore not surprising that the state of insulin resistance that typically accompanies essential hypertension 24 was shown to be improved by treatment with ACE inhibitors. 7, 11, 25, 26 The exact mechanisms of this effect remain controversial. Improved capillary blood flow 27 may contribute to it but is clearly not the main mechanism, because other vasodilators have no such properties. In previous studies 12 we demonstrated that this is a direct effect of the B 2 R on insulindependent glucose transport because it is not mediated by downstream autacoids; indeed it could be abolished by selective B 2 R antagonists but not by the prostaglandin inhibitor indomethacin or the NO synthase inhibitor nitro-Larginine methyl ester (L-NAME). Although other investigators have corroborated these findings, 28 there is still no unanimous agreement as to the role of local tissue mediators in this aspect of the B 2 R function. 9, 29 Nevertheless, it is possible that alterations in number or function of B 2 R may contribute to the diminished insulin sensitivity encountered in conditions, such as normal aging or essential hypertension.
In a recent study, we found that the B 1 R, which is physiologically inert, was actually overexpressed in B 2 R knockout mice at baseline and was further upregulated during hypertensive procedures. 17 Furthermore, under those conditions it appeared to take over part of the hemodynamic effect of the missing B 2 R. This would explain why the B 2 R knockout mice have no lesser antihypertensive response to ACE inhibition than the wild-type, as described several years ago. 30 These findings are consistent with the BP results of the current study, in which the BP response to ACE inhibition remained unaffected. The cardiovascular phenotype of B 2 R knockout mice is a matter of controversy in the literature, as some authors have found them to be normotensive at baseline 31 whereas others have found them to be hypertensive, 32 which is in agreement with our own current and previous 17 data. These discrepancies are difficult to explain because they may reflect not only the genetically engineered mutation but also selection, genetic drift, and epistatic interactions that may occur in small-size colonies. 33 Regardless of cardiovascular phenotype, the current study was designed to further clarify the metabolic role of the B 2 R and to explore whether the upregulated B 1 R may also be capable of taking over part of the metabolic properties of bradykinin. Additional studies using specific B 1 R antagonists would, of course, further corroborate or refute these data, because it is possible that resistance to insulin might become further accentuated during B 1 R blockade. Nevertheless, the increased insulin resistance in the B 2 RϪ/Ϫ mice suggests that the upregulated B 1 R receptor does not take over the metabolic function of the missing B 2 R. This evidence may also be taken to further support the notion that unlike the hemodynamic action, the metabolic action is a direct effect of the B 2 R, not mediated by downstream autacoids such as NO or prostaglandins, which may respond to stimulation by other receptors. One could offer possible speculative explanations for the failure of the B 1 R to exert direct effects, for example, failure to internalize.
In wild-type mice, analysis of the mRNA expression of the B 1 R and B 2 R in skeletal muscle, heart, and adipose tissues, that is, tissues that are most dependent on insulin for glucose uptake, revealed that the insulin infusion induced also an upregulation of B 2 R. This receptor is constitutively present, and its upregulation by this maneuver is a novel finding. This is consistent with the notion that this bradykinin receptor plays an important role in insulin-mediated glucose transport in skeletal muscle, adipose tissue, and heart, although differences in degree of overexpression among tissues are difficult to explain. An unexpected finding, however, was that along with the B 2 R upregulation, there was also in these animals an increase in B 1 R gene expression, although to a much lesser extent than the B 2 R and to degrees varying widely among different tissues. As mentioned earlier, it is known that the B 1 R is not expressed under physiological conditions, but pathological conditions such as inflammation and tissue damage induce its expression in vascular and nonvascular tissues. 15 The inducibility of this receptor was first described in isolated rabbit aorta, in which a time-dependent and protein synthesis-dependent contractile response to des-Arg-BK was observed. 34, 35 It was recently shown that the BK B 1 R upregulation involves activation of protein kinases through participation of nuclear factor-B, identified in the promoter region of the B 1 R gene. 36 -38 Insulin receptor activation also involves mobilization of tyrosine kinase, 39 similar to the mobilization induced by cytokines, which may explain the inducibility of B 1 R by insulin. The functional significance, if any, of this phenomenon, remains unclear at this time. Usually, biologic responses have a teleologically plausible, even if speculative, justification. Accordingly, it is easy to explain why deletion of B 2 R would elicit induction of B 1 R, which is also capable of stimulating release of local tissue mediators such as NO and prostaglandins 40 and hence maintain local tissue perfusion. Likewise, it is easy to see why infusion of insulin and glucose would upgrade expression of the B 2 R; however, a change in transcriptional regulation of the B 1 R gene by this maneuver, especially in the presence of a normally functioning upgraded B 2 R, is difficult to explain away when the B 1 R can have no impact on glucose metabolism. Of course, it should also be kept in mind that increased B 1 R mRNA does not necessarily imply increased generation of B 1 R protein, although it is strongly suggestive.
Other pathological conditions, in which upregulation of the B 1 R has been described in various tissues, include regional ischemia 41 and hyperglycemia caused by diabetes mellitus induced by streptozotocin. 42, 43 All of these experiments, however, have only explored the hemodynamic functions assumed by the B 1 R, which become activated even in the presence of functional B 2 R and contribute to the tissueprotective effects of BK through enhanced release of local vasoactive mediators. Besides, streptozotocin diabetes is akin to type 1 (insulin-deficient) diabetes and therefore would not be a suitable model for assessing the metabolic role of BK receptors on the insulin-resistance characteristic of type 2 diabetes.
In summary, the present data confirm and amplify our previous finding that the absence of a functional B 2 R induces overexpression of the B 1 R in a variety of tissues. They further confirm previous reports by us and others that the metabolic function of bradykinin, that is, enhanced insulin-dependent glucose transport, is a function of the B 2 R because its absence causes a state of considerable insulin resistance; they also suggest that this metabolic effect probably is exerted directly, for example, without mediation by local autacoids. Unlike the hemodynamic effects of bradykinin, which, in the absence of B 2 R can be assumed by the upgraded B 1 R, the metabolic effects of bradykinin appear to be exerted exclusively through the B 2 R.
